Core Viewpoint - The company is steadily advancing the commercialization of Anglatide tablets [1] Group 1 - The company is actively engaging with investors regarding its progress in the commercialization of Anglatide tablets [1]

Core Viewpoint - The company, Zhongsheng Pharmaceutical (002317), addressed investor inquiries on November 20, indicating that shareholders should refer to the company's periodic reports for detailed information [1]. Group 1 - The company is actively engaging with investors through an interactive platform [1]. - The company emphasizes the importance of periodic reports for understanding shareholder information [1].

Market Overview - The Chinese medicine sector experienced a decline of 0.21% on November 20, with Kanghui Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - *ST Changyao: Closed at 2.83, up 19.92% with a trading volume of 763,900 shares and a turnover of 197 million yuan [1] - Jinhua Co., Ltd.: Closed at 69.8, up 7.15% with a trading volume of 577,400 shares and a turnover of 505 million yuan [1] - Tailong Pharmaceutical: Closed at 7.44, up 3.33% with a trading volume of 344,200 shares and a turnover of 25.2 million yuan [1] - Conversely, Kanghui Co., Ltd. saw a decline of 3.72%, closing at 22.26 with a trading volume of 27,400 shares and a turnover of 61.69 million yuan [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 143 million yuan from institutional investors, while retail investors saw a net inflow of 133 million yuan [2] - Key stocks with significant capital flow included: - Jinhua Co., Ltd.: Institutional net inflow of 99.64 million yuan, retail net outflow of 79.86 million yuan [3] - Zhongsheng Pharmaceutical: Institutional net inflow of 92.18 million yuan, retail net outflow of 51.91 million yuan [3] - Tailong Pharmaceutical: Institutional net inflow of 25.82 million yuan, retail net outflow of 31.90 million yuan [3]

Core Viewpoint - The stock of Zhongsheng Pharmaceutical has experienced fluctuations, with a recent decline of 2.02% and a total market capitalization of 18.936 billion yuan, despite an overall increase of 86.44% year-to-date [1] Financial Performance - For the period from January to September 2025, Zhongsheng Pharmaceutical reported a revenue of 1.889 billion yuan, a year-on-year decrease of 1.01%, while the net profit attributable to shareholders increased by 68.40% to 251 million yuan [2] - The company has cumulatively distributed 2.019 billion yuan in dividends since its A-share listing, with 502 million yuan distributed over the past three years [3] Stock Market Activity - The stock has seen significant trading activity, with a net outflow of 67.267 million yuan in major funds recently, and it has appeared on the trading leaderboard seven times this year [1] - The stock price has fluctuated, with a recent 5-day decline of 5.75% and a 20-day increase of 20.89% [1] Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 18.90% to 72,900, while the average number of circulating shares per person increased by 23.31% to 10,445 shares [2] - Notable institutional shareholders include Hong Kong Central Clearing Limited and several funds from Xingquan, indicating a mix of new and increasing positions among major shareholders [3]

Core Viewpoint - The company aims to position itself as a health enterprise focusing on traditional Chinese medicine (TCM) and innovation, with traditional Chinese patent medicine as its business foundation [2] Group 1: Business Strategy - The company is committed to the strategy of "TCM as the foundation, innovation leading," which emphasizes the importance of traditional Chinese medicine in its operations [2] - The company is actively conducting post-marketing evaluations of traditional Chinese patent medicines and working on the revival of dormant TCM products [2] - The company is exploring the development of classic TCM formulas and hospital preparations, as well as expanding its product design and development in the TCM health sector [2] Group 2: Market Expansion - The company is focused on solidifying its TCM business foundation while also expanding the sales market for traditional Chinese patent medicines [2]

Core Viewpoint - The company announced that its drug, Anglatide Tablets (brand name: Anruwei®), is effective for treating adult patients with uncomplicated influenza A, showing strong inhibitory activity against various strains of influenza viruses, including those resistant to Oseltamivir and Baloxavir [2] Group 1 - The drug is specifically indicated for adult patients with uncomplicated influenza A [2] - Preclinical research indicates the drug's effectiveness against multiple influenza virus strains, including those resistant to other antiviral medications [2]

Market Overview - The Shanghai Composite Index rose by 0.18% on November 19, with 10 industries experiencing gains, led by non-ferrous metals and petroleum & petrochemicals, which increased by 2.39% and 1.67% respectively. Conversely, the comprehensive and real estate sectors saw declines of 3.08% and 2.09% respectively [1] Capital Flow Analysis - The main capital flow showed a net outflow of 40.955 billion yuan across the two markets, with 7 industries experiencing net inflows. The defense and military industry led with a net inflow of 3.610 billion yuan and a daily increase of 1.11%, followed by the banking sector with a 0.92% increase and a net inflow of 1.265 billion yuan [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector declined by 1.28%, with a total net outflow of 4.880 billion yuan. Out of 477 stocks in this sector, 44 rose, including 3 that hit the daily limit, while 431 fell, with 4 hitting the lower limit. Notably, 90 stocks had net inflows, with Dongfang Ocean leading at 245 million yuan [2][4] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Dongfang Ocean: +9.96% with a net inflow of 24.473 million yuan - Yaoming Kangde: +0.95% with a net inflow of 7.010 million yuan - Zhonghong Medical: +10.39% with a net inflow of 6.370 million yuan [2] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - Zhongsheng Pharmaceutical: -4.73% with a net outflow of 234.806 million yuan - Maijie Medical: -0.92% with a net outflow of 173.607 million yuan - Hainan Haiyao: -10.00% with a net outflow of 156.557 million yuan [4]

Group 1 - The core point of the news is that Zhongsheng Pharmaceutical's stock has declined by 5.11%, with a current price of 22.65 CNY per share and a total market capitalization of 19.251 billion CNY [1] - Zhongsheng Pharmaceutical, established on December 31, 2001, and listed on December 11, 2009, is primarily engaged in the research, production, and sales of pharmaceuticals [1] - The company's main business revenue composition includes: Traditional Chinese Medicine sales at 53.03%, chemical drug sales at 38.12%, Chinese medicinal materials and decoction pieces sales at 6.13%, raw materials and intermediates sales at 2.14%, and other sales at 0.58% [1] Group 2 - From the perspective of fund holdings, one fund under Taixin Fund has a significant position in Zhongsheng Pharmaceutical, with Taixin Smart Quantitative Stock Mixed Fund A (013033) holding 15,000 shares, accounting for 1.94% of the fund's net value [2] - The estimated floating loss for the fund today is approximately 18,300 CNY [2] - Taixin Smart Quantitative Stock Mixed Fund A (013033) was established on May 22, 2025, with a latest scale of 12.5156 million CNY and a cumulative return of 18.58% since inception [2]

Core Viewpoint - The company Zhongsheng Pharmaceutical (002317.SZ) has announced that its drug Angladiwei tablets (brand name: Anruiwei®) is effective for treating adult patients with uncomplicated influenza A, showing strong inhibitory activity against various influenza virus strains, including those resistant to Oseltamivir and Baloxavir [1] Company Summary - The Angladiwei tablets are specifically indicated for adult patients with uncomplicated influenza A [1] - Preclinical research indicates the drug's effectiveness against multiple influenza virus strains, including highly pathogenic avian influenza and resistant strains [1]

格隆汇11月19日丨众生药业(002317.SZ)在投资者互动平台表示，公司的昂拉地韦片（商品名：安睿威 ®）适用于成人单纯性甲型流感患者的治疗，临床前研究结果表明，对包括奥司他韦耐药株、高致病性 禽流感病毒株和巴洛沙韦耐药株等在内的多种不同亚型流感病毒株具有强大的抑制活性。 ...